EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The Influence of GBA and LRRK2 on Mood Disorders in Parkinson's Disease

Jake DeBroff, Nurit Omer, Batsheva Cohen, Nir Giladi, Meir Kestenbaum, Julia C Shirvan, Jesse M Cedarbaum, Mali Gana-Weisz, Orly Goldstein, Avi Orr-Urtreger, Anat Mirelman iD, Avner Thaler iD

Movement Disorders Clinical Practice · 2023-04 · 10 (4) · 606-616

DOI: 10.1002/mdc3.13722 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 21.03.2023. Verfasst von Jake DeBroff und 11 weiteren Autor:innen. Beteiligte Einrichtung: Sackler School of Medicine Tel-Aviv University. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Biogen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mood disorders have emerged as major non‐motor comorbidities in Parkinson's disease (PD) even at the prodromal stage of the disease. Mutations in the LRRK2 and GBA genes are common among Ashkenazi Jews, with more severe phenotype reported for GBA ‐PD.

Objective

To explore the association between genetic status and mood related disorders before and after diagnosis of PD and the association between mood‐related medications, phenotype, and genetic status.

Methods

Participants were genotyped for mutations in the LRRK2 and GBA genes. State of depression, anxiety and non‐motor features were evaluated using validated questionnaires. History of mood disorders prior to diagnosis of PD and use of mood‐related medications were assessed.

Results

The study included 105 idiopathic PD (iPD), 55 LRRK2 ‐PD and 94 GBA ‐PD. Scores on mood related questionnaires and frequency of depression and anxiety before diagnosis were similar between the groups ( p >0.05). However, more GBA ‐PD patients used mood related medications before PD diagnosis than LRRK2 ‐PD and iPD (16.5% vs 7.1% and 8.2%, p =0.044). LRRK2 ‐PD and GBA ‐PD receiving mood‐related medications at time of assessment had worse motor and non‐motor phenotype compared to those that did not ( p

Schlagwörter

Stichwörter der Autor:innen

GBALRRK2Parkinson's diseaseanxietydepression

Autor:innen und Institutionen

  • Sackler School of Medicine Tel-Aviv University.
  • Movement Disorders Unit Neurological Institute, Tel-Aviv Medical Center.
  • Laboratory of Early Markers of Neurodegeneration Neurological Institute, Tel-Aviv Medical Center.
  • Sagol School of Neuroscience Tel-Aviv University.
  • Neurology department Meir Hospital Kfar-Saba Israel.
  • Biogen Inc. Cambridge MA USA.

ORCID-Profile: Anat Mirelman, Avner Thaler

Förderung

  • Biogen

Zitieren

APA

DeBroff, J., Omer, N., Cohen, B., Giladi, N., Kestenbaum, M., Shirvan, J. C., Cedarbaum, J. M., Gana-Weisz, M., Goldstein, O., Orr-Urtreger, A., Mirelman, A., & Thaler, A. (2023). The Influence of GBA and LRRK2 on Mood Disorders in Parkinson's Disease. Movement Disorders Clinical Practice, 10(4), 606-616. https://doi.org/10.1002/mdc3.13722

Vancouver

DeBroff J, Omer N, Cohen B, Giladi N, Kestenbaum M, Shirvan JC, et al. The Influence of GBA and LRRK2 on Mood Disorders in Parkinson's Disease. Movement Disorders Clinical Practice. 2023;10(4):606-616. doi:10.1002/mdc3.13722

BibTeX
@article{DeBroff2023,
  author = {DeBroff, Jake and Omer, Nurit and Cohen, Batsheva and Giladi, Nir and Kestenbaum, Meir and Shirvan, Julia C and Cedarbaum, Jesse M and Gana-Weisz, Mali and Goldstein, Orly and Orr-Urtreger, Avi and Mirelman, Anat and Thaler, Avner},
  title = {The Influence of GBA and LRRK2 on Mood Disorders in Parkinson's Disease},
  journal = {Movement Disorders Clinical Practice},
  year = {2023},
  volume = {10},
  number = {4},
  pages = {606--616},
  doi = {10.1002/mdc3.13722}
}
Kostenlos starten →